Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression

Academic Article
Publication Date:
2021
Short description:
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression / Bonnal, R.J.P., Rossetti, G., Lugli, E., De Simone, M., Gruarin, P., Brummelman, J., Drufuca, L., Passaro, M., Bason, R., Gervasoni, F., Della Chiara, G., D'Oria, C., Martinovic, M., Curti, S., Ranzani, V., Cordiglieri, C., Alvisi, G., Mazza, E.M.C., Oliveto, S., Silvestri, Y., et al.. - In: NATURE IMMUNOLOGY. - ISSN 1529-2908. - 22:6(2021), pp. 735-745. [10.1038/s41590-021-00930-4]
abstract:
Regulatory T (Treg) cells are a barrier for tumor immunity and a target for immunotherapy. Using single-cell transcriptomics, we found that CD4+ T cells infiltrating primary and metastatic colorectal cancer and non-small-cell lung cancer are highly enriched for two subsets of comparable size and suppressor function comprising forkhead box protein P3+ Treg and eomesodermin homolog (EOMES)+ type 1 regulatory T (Tr1)-like cells also expressing granzyme K and chitinase-3-like protein 2. EOMES+ Tr1-like cells, but not Treg cells, were clonally related to effector T cells and were clonally expanded in primary and metastatic tumors, which is consistent with their proliferation and differentiation in situ. Using chitinase-3-like protein 2 as a subset signature, we found that the EOMES+ Tr1-like subset correlates with disease progression but is also associated with response to programmed cell death protein 1–targeted immunotherapy. Collectively, these findings highlight the heterogeneity of Treg cells that accumulate in primary tumors and metastases and identify a new prospective target for cancer immunotherapy.
Iris type:
1.1 Articolo in rivista
List of contributors:
Bonnal, R. J. P.; Rossetti, G.; Lugli, E.; De Simone, M.; Gruarin, P.; Brummelman, J.; Drufuca, L.; Passaro, M.; Bason, R.; Gervasoni, F.; Della Chiara, G.; D'Oria, C.; Martinovic, M.; Curti, S.; Ranzani, V.; Cordiglieri, C.; Alvisi, G.; Mazza, E. M. C.; Oliveto, S.; Silvestri, Y.; Carelli, E.; Mazzara, S.; Bosotti, R.; Sarnicola, M. L.; Godano, C.; Bevilacqua, V.; Lorenzo, M.; Siena, S.; Bonoldi, E.; Sartore-Bianchi, A.; Amatu, A.; Veronesi, G.; Novellis, P.; Alloisio, M.; Giani, A.; Zucchini, N.; Opocher, E.; Ceretti, A. P.; Mariani, N.; Biffo, S.; Prati, D.; Bardelli, A.; Geginat, J.; Lanzavecchia, A.; Abrignani, S.; Pagani, M.
Authors of the University:
NOVELLIS PIERLUIGI
VERONESI GIULIA
Handle:
https://iris.unisr.it/handle/20.500.11768/117656
Published in:
NATURE IMMUNOLOGY
Journal
  • Overview

Overview

URL

https://www.nature.com/articles/s41590-021-00930-4#data-availability
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.6.2.0